Volume 4, Issue 6, December 2016, Page: 64-67
HLA Alloantibodies in Multiparous Women at Abidjan
N’guessan Koffi, Department of Immunology-Hematology and Cancerology, Felix Houphouët Boigny University, Abidjan, Ivory Coast
Akre Dagra Paul, Department of Immunology, Allassane Ouattara University, Bouake, Ivory Coast
Dasse Sery Romuald, Department of Immunology-Hematology and Cancerology, Felix Houphouët Boigny University, Abidjan, Ivory Coast
Gobey Richard Arthur, Department of Immunology, Allassane Ouattara University, Bouake, Ivory Coast
Fizet Dominique, Department of Cellular Immunology, French Blood Agency, Bordeaux, France
Seka Seka Joseph, Department of Immunology, Allassane Ouattara University, Bouake, Ivory Coast
Sombo Mambo François, Department of Immunology-Hematology and Cancerology, Felix Houphouët Boigny University, Abidjan, Ivory Coast
Received: Oct. 4, 2016;       Accepted: Nov. 23, 2016;       Published: Dec. 29, 2016
DOI: 10.11648/j.iji.20160406.13      View  3119      Downloads  74
Abstract
Serum of multiparous women can contain HLA polyclonal antibodies which can be used as reagents for serological typing of HLA class I and class II. The aim of this study was to investigate an alloimmunization of multiparous women and to identify HLA polyclonal antibodies which could be useful as laboratory reagents in view of the future HLA unit of the Department of Immunology at Abidjan. In an experimental and analytic study, we screened HLA antibodies using microlymphocytotoxicity test on sera of 121 multiparous women aged from 18 to 70 years old, in apparent good health, transfused or no-transfused and with at least two parities. 37.19% of the multiparous women were alloimmunized. 13 women were sensitized to HLA class I, 18 to HLA class II and 14 were both sensitized to class I and class II. Specificity of the screened antibodies was identified at 17.78%. HLA-B7 specificity (Class I) was 37.5% and class II specificity (HLA-DR4, DR7, DR13, DR13+14, DRw52) was 62.5%. Specificity was evaluated by the correlation coefficient. For class I specificity correlation coefficients were ranged from 0.79 to 1, while for class II specificities, correlation coefficients were ranged from 0.54 to 0.9. Screening of HLA antibodies on multiparous women at Abidjan was positive and specificities were determined. This enabled authors to the possibility of using multiparous women sera as a source of production of polyclonal antibodies for serological HLA typing in the HLA unit of the Department of Immunology at Abidjan.
Keywords
HLA Alloimmunization, Multiparous Women, Microlymphocytotoxicity, Ivory Coast
To cite this article
N’guessan Koffi, Akre Dagra Paul, Dasse Sery Romuald, Gobey Richard Arthur, Fizet Dominique, Seka Seka Joseph, Sombo Mambo François, HLA Alloantibodies in Multiparous Women at Abidjan, International Journal of Immunology. Vol. 4, No. 6, 2016, pp. 64-67. doi: 10.11648/j.iji.20160406.13
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Navarrete CV. Human Leucocyte antigens. In Practical transfusion medicine. Michael FM, Derwood HP. Blackwell publishing, Oxford 2002, pp 36-49.
[2]
Murphey CL, Forsthuber TG. Trends in HLA antibody screening and identification and their role in transplantation. Expert Rev Clin Immunol. 2008; 4: 391-9.
[3]
Mason Y, Heine U, Stuhmiller GM. Human Leukocyte antigens. In Immunohematology-principles and practice. Lippincott-Raven publishers, Philadelphia 1998, pp 376-379.
[4]
Little A, Steven GE, Alejandro M. Histocompatibility. In: Post graduate haematlogy. Victor H, Daniel C, Edward GD. Blackwell publishing, Massachusets 2005, pp 395-413.
[5]
Kleinman S, Chan P, Robillard P. Risk associated with transfusion of celllular blood components in Canada. Tranfus Med Rev. 2003; 17: 120-62.
[6]
Klein J, Sato A. The HLA system. First of two years. New Engl J Med. 2000; 343: 702-9.
[7]
Choo SY. The HLA system: genetics immunology, clinical testing and clinical implications. Yonsei Med J. 2007; 48: 11-23.
[8]
Terasaki PI, Mcclelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998-1000.
[9]
Prescott SL, Taylor A, Ropert J, Wahdan A, Noakes P, Thornton C, Dunstan J, Upham JW. Maternal reactivity to fetal alloantigens is related to newborn immune responses and subsequent allergic disease. Clin Exp Allergy 2005; 35 (4): 417-25.
[10]
Tomicić M, Starcević M, Bux J, Zach V, Hundrić-Haspl Z, Drazić V, Grahovac B. Severe neonatal neutropenia due to anti-human leucocyte antigen B49 alloimmunization only: a case report. Transfus Med. 2003; 13 (4): 233-7.
[11]
Richard AG, Thomas JK, Barbara AO.-Réactions d’hypersensibilité.-In Immunologie, le cours de Janis Kuby. Richard AG, Thomas JK, Barbara AO. Dunod, Paris 2003, pp 395-421.
[12]
Pene F, Sombo MF, Cabannes R. Immunisation foeto-maternelle anti-HLA en Côte d’Ivoire. Ann Univ Abidjan 1970; 14: 191-6.
[13]
Vilches M, Nieto A. Analysis of pregnancy-induced anti-HLA antibodies using luminex platform. Transplant Proc. 2015; 47 (9): 2608-10.
[14]
Masson E, Vidal C, Deschamps M, Bongain S, Thevenin C, Dupont I, Rietmulher D, Pouthier F, Mongaillard G, Chabod J, Ferrand C, Tiberghien P, Rebibou JM. Incidence and risk factors of anti-HLA immunization after pregnancy. Hum Immunol. 2013; 74 (8): 946-51.
[15]
Morin-Papunel L, Tiilikainen A, Hartkainen-Sorri AL. Maternal HLA immunization during pregnancy: presence of anti HLA antibodies in half of multigravidous women. Med Biol. 1984; 62 (6): 323-5.
[16]
Colombani, J. "HLA: Fonctions immunitaires et applications médicales" John Libbey Eurotext. Paris 1993, pp 285.
[17]
Houissa B, Abdelkefi S, Bouslama M, Naggara M, Zaier M, Hmida S, Yacoub S. The utility of class I HLA antibodies screening in Tunisian obstetric departement in order to select good HLA typing reagents. Ann Biol Clin. 2003; 61 (4): 435-9.
[18]
Rafoux C, Lepage V.-Polymorphisme sérologique de classe I. La série allélique A, B, C.-in HLA. Complexe Majeur d’Histocompatibilité de l’Homme, Jean Dausset, Marika PL. Flammarion Medecine Sciences. Paris 1989, pp 64-100.
[19]
Umapathy S1, Shankarkumar A, Ramrakhiyani V, Ghosh K. Role of anti-human lymphocyte culture cytotoxic antibodies in recurrent spontaneous pregnancy loss women. J Hum Reprod Sci. 2011; 4 (1): 17-9.
[20]
Dankers MK, Roelen DL, Korfage N, de Lange P, Witvliet M, Sandkuijl L, Doxiadis II, Claas FH. Differential immunogenicity of paternal HLA Class I antigens in pregnant women. Hum Immunol. 2003; 64: 600-6.
[21]
Hönger G, Fornaro I, Granado C, Tiercy JM, Hösli I, Schaub S. Frequency and determinants of pregnancy-induced child-specific sensitization. Am J Transplant. 2013; 13: 746-53.
Browse journals by subject